Vaxcyte Inc (PCVX) Financial Statements

PCVX Financial Data

EBITDA$-741.77M

Revenue (TTM)$0.00

Gross Profit (TTM)$0.00

Gross Margin—

Operating Margin—

ROE-28.55%

ROA-25.53%

Debt/Equity0.04

Current Ratio7.91

FCF$-712.55M

FCF Yield-9.78%

Piotroski F-Score—

Rev/Share (TTM)—

50-Day MA$58.61

200-Day MA$46.39

Shares Outstanding0.13B

PCVX Computed Insights

FCF$-712.55M

FCF Growth Rate—

EPS Growth (CAGR)—

WACC10.00%

Income Statement

Balance Sheet

Cash Flow Statement

PCVX Financial Statements & Data

Vaxcyte Inc (PCVX) financial data including income statement, balance sheet, and cash flow statement. This page provides a comprehensive view of Vaxcyte Inc's financial performance and position as a Healthcare company.

Trailing twelve-month (TTM) revenue is $0.00. Gross profit (TTM) is $0.00. EBITDA is $-741.77M. Earnings per share (EPS) is $-5.63. The P/E ratio is -9.50. Market capitalization is $7.28B.

Free cash flow (FCF) is $-712.55M. Weighted average cost of capital (WACC) is 10.00%.

Historical revenue data covers 7 years from FY19 to FY25. Net income history spans 7 years. Free cash flow and capital expenditure data spans 7 years. GoodMoat displays interactive charts for revenue, net income, FCF vs CAPEX, and cash-to-debt ratios to help investors identify financial trends.

Use Vaxcyte Inc's financial data to assess the company's earnings quality, balance sheet health, and cash generation. Compare key metrics across periods to identify trends before making investment decisions with GoodMoat's valuation tools.